摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3β,5β)-3-amino-12-oxocholan-24-oic acid methyl ester | 721945-11-5

中文名称
——
中文别名
——
英文名称
(3β,5β)-3-amino-12-oxocholan-24-oic acid methyl ester
英文别名
(3beta,5beta)-3-Amino-12-oxocholan-24-oic acid methyl ester;methyl (4R)-4-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-amino-10,13-dimethyl-12-oxo-1,2,3,4,5,6,7,8,9,11,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoate
(3β,5β)-3-amino-12-oxocholan-24-oic acid methyl ester化学式
CAS
721945-11-5
化学式
C25H41NO3
mdl
——
分子量
403.605
InChiKey
CFYQWONALRTRRL-XHPWGDQZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    29
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.92
  • 拓扑面积:
    69.4
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Gastrin releasing peptide compounds
    申请人:——
    公开号:US20040136906A1
    公开(公告)日:2004-07-15
    New and improved compounds for use in radiodiagnostic imaging or radiotherapy having the formula M-N—O—P-G, wherein M is the metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy to a patient using the compounds of the invention are also provided. A method for preparing a diagnostic imaging agent from the compound is further provided. A method for preparing a radiotherapeutic agent is further provided.
    新的和改进的化合物,可用于放射性诊断成像或放射治疗,具有公式M-N—O—P-G,其中M是螯合剂(以与属放射性核素或未结合的形式),N—O—P是连接物,G是GRP受体靶向肽。本发明还提供了利用这些化合物对患者进行成像和/或放射治疗的方法。还提供了从该化合物制备诊断成像试剂的方法。还提供了制备放射治疗试剂的方法。
  • Linkers for radiopharmaceutical compounds
    申请人:De Haën Christoph
    公开号:US20060241018A1
    公开(公告)日:2006-10-26
    A new and improved method for extending the half life of pharmaceutical compounds for use in diagnostic imaging or therapy uses a novel linker to attach a diagnostic or therapeutic moiety to a targeting peptide or another diagnostic or therapeutic moiety. The resulting compound may have the general formula M-N-O-P-Q, wherein M is the diagnostic or therapeutic moiety, N-O-P is the linker of the present invention, and Q is the targeting peptide. In another embodiment the compounds may have the formula M-N-O-P-M, wherein M is independently a diagnostic or therapeutic moiety and N-O-P is the linker of the invention. Methods for imaging or treating a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound are further provided. Methods for radiotherapy of a patient using the compounds are further provided, as are methods for preparing a radiotherapeutic agent from the compounds.
    一种新的、改进的方法,用于延长药物化合物的半衰期,用于诊断成像或治疗,使用一种新型连接剂将诊断或治疗基团连接到靶向肽或另一个诊断或治疗基团上。得到的化合物可能具有一般公式M-N-O-P-Q,其中M是诊断或治疗基团,N-O-P是本发明中的连接剂,而Q是靶向肽。在另一种实施方案中,化合物可能具有公式M-N-O-P-M,其中M是独立的诊断或治疗基团,N-O-P是该发明中的连接剂。还提供了使用该发明中化合物进行成像或治疗患者的方法。还提供了制备诊断成像剂的方法和试剂盒。还提供了使用该化合物进行放射治疗的方法,以及制备放射治疗剂的方法。
  • Gastrin Releasing Peptide Compounds
    申请人:Cappelletti Enrico
    公开号:US20070231257A1
    公开(公告)日:2007-10-04
    New and improved compounds for use in radiodiagnostic imaging or radiotherapy having the formula M-N—O—P-G, wherein M is the metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy to a patient using the compounds of the invention are also provided. A method for preparing a diagnostic imaging agent from the compound is further provided. A method for preparing a radiotherapeutic agent is further provided.
    新的并且改良的化合物,用于放射性诊断成像或放射治疗,其化学式为M-N-O-P-G,其中M为螯合剂(以属放射性核素形式复合或未复合),N-O-P为连接剂,G为GRP受体靶向肽。本发明还提供了使用该化合物对患者进行成像和/或放射治疗的方法。此外,还提供了一种从该化合物制备诊断成像试剂的方法。还提供了一种制备放射性治疗试剂的方法。
  • GASTRIN RELEASING PEPTIDE COMPOUNDS
    申请人:Cappelletti Enrico
    公开号:US20110052491A1
    公开(公告)日:2011-03-03
    New and improved compounds for use in diagnostic imaging or therapy having the formula M—N—O—P—G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.
    本发明涉及用于诊断成像或治疗的新型化合物,其化学式为M—N—O—P—G,其中M是光学标记或螯合剂(以与属放射性核素形成络合物或非络合形式存在),N—O—P是连接剂,G是GRP受体靶向肽。本发明还提供了使用该化合物进行患者成像和/或提供放射治疗或光疗的方法。本发明还提供了制备诊断成像剂的方法和试剂盒。本发明还提供了制备放射治疗剂的方法和试剂盒。
  • Linkers For Radiopharmaceutical Compounds
    申请人:De Haen Christoph
    公开号:US20110280802A1
    公开(公告)日:2011-11-17
    A new and improved method for extending the half life of pharmaceutical compounds for use in diagnostic imaging or therapy uses a novel linker to attach a diagnostic or therapeutic moiety to a targeting peptide or another diagnostic or therapeutic moiety. The resulting compound may have the general formula M-N—O—P-Q, wherein M is the diagnostic or therapeutic moiety, N—O—P is the linker of the present invention, and Q is the targeting peptide. In another embodiment the compounds may have the formula M-N—O—P-M, wherein M is independently a diagnostic or therapeutic moiety and N—O—P is the linker of the invention. Methods for imaging or treating a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound are further provided. Methods for radiotherapy of a patient using the compounds are further provided, as are methods for preparing a radiotherapeutic agent from the compounds.
    一种改进的新方法,用于延长药物化合物的半衰期,以用于诊断成像或治疗,使用新型连接剂将诊断或治疗基团连接到靶向肽或另一个诊断或治疗基团上。所得化合物可能具有一般公式M-N-O-P-Q,其中M为诊断或治疗基团,N-O-P为本发明的连接剂,Q为靶向肽。在另一实施例中,化合物可能具有公式M-N-O-P-M,其中M独立地为诊断或治疗基团,N-O-P为本发明的连接剂。还提供了使用本发明化合物进行成像或治疗患者的方法。还提供了制备诊断成像剂的方法和工具包。还提供了使用化合物进行放射治疗的方法,以及制备放射治疗剂的方法。
查看更多

同类化合物

(5β)-17,20:20,21-双[亚甲基双(氧基)]孕烷-3-酮 (5α)-2′H-雄甾-2-烯并[3,2-c]吡唑-17-酮 (3β,20S)-4,4,20-三甲基-21-[[[三(异丙基)甲硅烷基]氧基]-孕烷-5-烯-3-醇-d6 (25S)-δ7-大发酸 (20R)-孕烯-4-烯-3,17,20-三醇 (11β,17β)-11-[4-({5-[(4,4,5,5,5-五氟戊基)磺酰基]戊基}氧基)苯基]雌二醇-1,3,5(10)-三烯-3,17-二醇 齐墩果酸衍生物1 黄麻属甙 黄芪皂苷III 黄芪皂苷 II 黄芪甲苷 IV 黄芪甲苷 黄肉楠碱 黄果茄甾醇 黄杨醇碱E 黄姜A 黄夹苷B 黄夹苷 黄夹次甙乙 黄夹次甙乙 黄夹次甙丙 黄体酮环20-(乙烯缩醛) 黄体酮杂质EPL 黄体酮杂质1 黄体酮杂质 黄体酮杂质 黄体酮EP杂质M 黄体酮EP杂质G(RRT≈2.53) 黄体酮EP杂质F 黄体酮6-半琥珀酸酯 黄体酮 17alpha-氢过氧化物 黄体酮 11-半琥珀酸酯 黄体酮 麦角甾醇葡萄糖苷 麦角甾醇氢琥珀酸盐 麦角甾烷-6-酮,2,3-环氧-22,23-二羟基-,(2b,3b,5a,22R,23R,24S)-(9CI) 麦角甾烷-3,6,8,15,16-五唑,28-[[2-O-(2,4-二-O-甲基-b-D-吡喃木糖基)-a-L-呋喃阿拉伯糖基]氧代]-,(3b,5a,6a,15b,16b,24x)-(9CI) 麦角甾烷-26-酸,5,6:24,25-二环氧-14,17,22-三羟基-1-羰基-,d-内酯,(5b,6b,14b,17a,22R,24S,25S)-(9CI) 麦角甾-8-烯-3-醇 麦角甾-8,24(28)-二烯-26-酸,7-羟基-4-甲基-3,11-二羰基-,(4a,5a,7b,25S)- 麦角甾-7,22-二烯-3-酮 麦角甾-7,22-二烯-17-醇-3-酮 麦角甾-5,24-二烯-26-酸,3-(b-D-吡喃葡萄糖氧基)-1,22,27-三羟基-,d-内酯,(1a,3b,22R)- 麦角甾-5,22,25-三烯-3-醇 麦角甾-4,6,8(14),22-四烯-3-酮 麦角甾-1,4-二烯-3-酮,7,24-二(乙酰氧基)-17,22-环氧-16,25-二羟基-,(7a,16b,22R)-(9CI) 麦角固醇 麦冬皂苷D 麦冬皂苷D 麦冬皂苷 B